Late Studies Show Popular Heartburn Medications Replace The Effect Of Bewitching Widely Prescribed Heart Narcotic
/* 468x60, */
Four of the most commonly prescribed heartburn medications shorten the benefit associated with clopidogrel, a widely used antiplatelet medication also conscious by its trade-mark name, Plavix. These findings by researchers at Medco Health Solutions, Inc. (NYSE: MHS) and the Indiana University School of Medicine were presented at the annual scientific meeting of the Society for Cardiovascular Angiography and Interventions (SCAI).
The study found that using any one of various different proton pump inhibitors (PPIs) in conjunction with clopidogrel increases the risk of hospitalization for a CV event by 51 percent, and that odd PPIs each significantly stand that risk as well, ranging from 39 percent to 61 percent. The four PPIs included in the recite were pantoprazole (Protonix(R)), esomeprazole (Nexium(R)), omeprazole (Prilosec(R)) and Lansoprazole (Prevacid(R)), which in sync accounted for about 96 percent of PPI cause in the study. Other PPI's, including rabeprazole (Aciphex(R)), were not included in the announce due to the patient count for these agents existence inadequate to outturn trustworthy results.
Clopidogrel is one of the world's most prescribed drugs, and ranked third in US pharmaceutical sales in 2008. PPIs are often taken along with clopidogrel to cut the risk of gastrointestinal bleeding, a feasible side-effect of the antiplatelet drug. While 41 percent of patients in the interpret were prescribed a PPI, a negligible quantity of them had experienced a severe bleeding problem.
"There's a growing target of evidence that PPIs section the effectiveness of clopidogrel and levy cardiovascular patients at a much higher risk - a huge concern given the colossal cipher of patients affected," said Dr. Robert Epstein, Medco's manager medical officer and one of the study researchers. "While this study confirms prior analysis in this area, it brings us a step too in our by showing that this is a hitch associated with each of the four most general PPIs."
The adverse cardiovascular events that were measured in the study accommodate myocardial infarction, unstable angina, transient ischemic attack/stroke, coronary revascularization or cardiovascular death.
The conversation is one of a series by Medco and Indiana University researchers certified as The Clopidogrel Outcomes Peruse that is examining factors impacting the effectiveness of clopidogrel and the associated clinical outcomes and costs. An fresh study conducted as factor of this evaluation effort inaugurate that the application of PPI therapy in conjunction with clopidogrel increases related hospital costs by at least 38 percent; the annual reward for patients on both a PPI and clopidogrel was $6,061 as compared to $4,400 for patients only enchanting clopidogrel. These findings will be presented this month at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
The Clopidogrel Outcomes Scan investigated medical and drugstore claims news of 16,690 patients who were fascinating clopidogrel next a stent procedure and tracked the glance at subjects for a 12-month amplitude from 2005 to 2006. The glance at compared a collection of 6,828 patients who were concurrently captivating a PPI and clopidogrel to a group of 9,862 patients who were by oneself taking clopidogrel. When PPIs were examined individually all of the associations were highly statistically significant.
To lodging a related question that has raised questions approximately the PPI/clopidogrel interaction, the researchers also looked at if or not PPIs independently boost the risk of a CV event. The results of this read create that there was no independent corollary from beguiling a PPI in the absence of clopidogrel. The study included 1,641 patients who had undergone a stent procedure but were not taking clopidogrel and compared CV affair hospitalizations of patients on a PPI to those not taking a PPI. These findings were recently presented at the American Feelings Association's Scientific Forum on Grade of Charge and Outcomes Research in Cardiovascular and Stroke (QCOR).
"Our study, along with a 2007 FDA check-up and other researchers' work, provides strong evidence that PPIs do not independently raise cardiovascular risks for stent patients and further strengthens the observation that this interplay exists between PPIs and clopidogrel and impairs the effectiveness of the antiplatelet drug," said Epstein. "Given the totality of the evidence generated on this interaction and the declared benefits of clopidogrel in reducing the risk of death, heart attack and stroke after coronary stenting, patients and their physicians should continue to assurance in the utilize of this medication and deliberate a PPI single when clearly indicated."
Medco Health Solutions, Inc (NYSE: MHS) is a valuable health care company, serving the needs of another than 60 million people. Medco, the world's most advanced pharmacy(R), provides clinically driven pharmacy services designed to advance the aspect of discomposure and lower complete health apprehension costs for private and public employers, health plans, labor unions and state agencies of all sizes, and for individuals served by Medicare Part D Prescription Drug Plans. Terminated its different Medco Therapeutic Resource Centers(R) and the Accredo Health Group, Medco's Speciality Pharmacy, the company is creating innovative models for the affliction of patients with chronic and conglomerate conditions. Medco is a chieftain in the emerging nature of personalized medicine and in applying evidence-based protocols to upgrade the knowledge of pharmacy - a major component in reforming America's health alarm system. Medco is ranked figure 45 on the Fortune 500 list, with 2008 revenues of amassed than $51 billion.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Reality of 1995. These statements include risks and uncertainties that may intention results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no debt to publicly renew any forward-looking statement, whether as a creature of new information, approaching events, or otherwise. Forward-looking statements in this press release should be evaluated cool with the risks and uncertainties that modify our business, expressly those mentioned in the Risk Factors decrease of the Company's Annual Report on Articulation 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Convert Commission.
Source: Medco Health Solutions, Inc
View drug information on PLAVIX.
/* 468x60, */
Last relative articles:
- Use Of Statins Increases The Risk Of Developing Type 2 Diabetes But Reduces Coronary Events
- Heart Failure Worse When Right Ventricle Goes Bad
- Cooling Inflammation For Healthier Arteries
- Experts Identify Why Women And African Americans Face A Greater Risk Of Dying From Heart Disease Than White Men And What Can Be Done About It
- New Book Helps Pharmacists Play Larger Role In Heart Health
- Novel Screening Technique Identifies New Effects Of Approved Drugs For Cardiovascular Disease
- Compound Shows Promise Against Intractable Heart Failure
- Researchers Find Air Pollution Linked To Progression Of Atherosclerosis
- Heart-Assist Device Helped Ready 16-Year-Old For Successful Surgery
- Seven Signs That May Warn Of A Rare Heart Condition
clopidogrel, clopidogrel compared, clopidogrel increases, taking clopidogrel, clopidogrel outcomes, ppi clopidogrel, conjunction clopidogrel, effectiveness clopidogrel, clopidogrel reducing, clopidogrel impairs